Only a handful of people Sinha pointed to a recent study published in the online journal of JAMA which found an association between high intakes of vitamins B6 and B12 and hip fractures in older women

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

They may also be necessary when certain medications interfere with B12 absorption or in any other diagnosed condition specifically impacting B12 uptake
However, many people need to supplement with vitamins for a variety of reasons
Oxidation and enhanced energy expenditure appeared to be vital in the proposed action of the peptide